Recent trading put Achillion Pharmaceuticals Incorporated stock at a 2.15 change from the 50 day moving average, which is +27.17%. The Company is engaged in providing Internet search, communication and digital content. The Company manages its business geographically: the Americas; Europe, the Middle East and Africa (EMEA), and Asia Pacific. The stock had previously closed at $13.04. A total of 2.83 million shares of the company’s stock traded hands.
Advertisement
The S&P 500, meanwhile, fell 20.62 or 0.98% to 2,078.58, as nine of 10 sectors closed in the red. 3 analysts have rated the company at hold.
The company has price-to-cash ratio of 38.66 and PEG ratio of 4.06. The biopharmaceutical company reported ($0.34) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.36) by $0.02. They presently have a $21.00 price objective on the biopharmaceutical company’s stock.
The company is a specialty biotechnology company, focuses on developing products for critical-care patients with respiratory disease and improving care in pulmonary medicine.
Isis Pharmaceuticals, Inc. (ISIS), and its subsidiary, Akcea Therapeutics, reported positive results from a Phase 2 study of ISIS-APO(a)Rx in which patients with high lipoprotein(a), or Lp(a), achieved reductions in Lp(a) of up to 94 percent, with a mean reduction of 71 percent.
LXRX is now valued at $1.35 billion. Analyst recommendation for this stocks stands at 1.90. The company has -56.07 value in price to sale ratio while price to book ratio was recorded as -5.85.
Tenaris S.A. (NYSE:TS) shares advanced 0.87% in last trading session and ended the day at $25.49.
Shares of Lexicon Pharmaceuticals, Inc.
French pharmaceutical company Sanofi has partnered with Lexicon Pharmaceuticals to develop and commercialise sotagliflozin, a new diabetes drug.
On the NY Stock Exchange, declining issues outnumbered advancing ones by a 2,489 to 638 margin. The Company focuses on the development of four drug candidates for the treatment of HCV: ACH-1625, a NS3 protease inhibitor for the treatment of HCV, which is being tested in a phase IIa clinical trial, ACH-2684, a NS3 protease inhibitor for the treatment of HCV, which is being tested in a phase I clinical trial; ACH-2928, a NS5A inhibitor for the treatment of HCV, which is being tested in a phase I clinical trial, and ACH-3102, a NS5A inhibitor for the treatment of HCV, which is being prepared for investigational new drug (IND), filing and initiation of a phase I clinical trial. The 52-week high of the share price is $1.82 and the 52-week low is $0.25. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
Advertisement
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision. This equates to the consensus earnings growth estimate for the last 12 months, and should not be mistaken for a long term growth estimate. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should, might occur.
